• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by IO Biotech Inc.

    12/18/23 5:14:19 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IOBT alert in real time by email
    SC 13G 1 tm2333024d1_sc13g.htm SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934 

    (Amendment No. )*

     

    IO Biotech, Inc. 

     

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

     

    (Title of Class of Securities)

     

    449778 10 9

     

    (CUSIP Number)

     

    August 9, 2023

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

       ¨ Rule 13d-1(d)
       x Rule 13d-1(b)
       ¨ Rule 13d-1(c)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    CUSIP No.   449778 10 9
    1.

    Names of Reporting Persons

    Samsara BioCapital, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    3,640,015 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    3,640,015 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    3,640,015 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    5.5% (3)

    12.

    Type of Reporting Person (See Instructions)

    PN

           

    (1)This Schedule 13G is filed by Samsara BioCapital, L.P. (“Samsara LP”), Samsara BioCapital GP, LLC (“Samsara GP”) and Dr. Srinivas Akkaraju (“Akkaraju”) (and together with Samsara LP, Samsara GP, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)These shares are held by Samsara LP. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is the managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.

     

    (3)This percentage is calculated based on 65,880,914 shares of Common Stock outstanding as of November 10, 2023, as reported in the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed by the Issuer with the Securities and Exchange Commission (the “SEC”) on November 13, 2023.

     

    2 

     

     

    CUSIP No.   449778 10 9
    1.

    Names of Reporting Persons

    Samsara BioCapital GP, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)    (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    3,640,015 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    3,640,015 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    3,640,015 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    5.5% (3)

    12.

    Type of Reporting Person (See Instructions)

    OO

           

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)These shares are held by Samsara LP. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is the managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.

     

    (3)This percentage is calculated based on 65,880,914 shares of Common Stock outstanding as of November 10, 2023, as reported in the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed by the Issuer with the SEC on November 13, 2023.

     

    3 

     

     

     

    CUSIP No.   449778 10 9
    1.

    Names of Reporting Persons

    Dr. Srinivas Akkaraju

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)    (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    3,640,015 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    3,640,015 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    3,640,015 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    5.5% (3)

    12.

    Type of Reporting Person (See Instructions)

    IN

           

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)These shares are held by Samsara LP. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is the managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.

     

    (3)This percentage is calculated based on 65,880,914 shares of Common Stock outstanding as of November 10, 2023, as reported in the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed by the Issuer with the SEC on November 13, 2023.

     

    4 

     

     

    Item 1.  
       
      (a) Name of Issuer
    IO Biotech, Inc.
      (b) Address of Issuer’s Principal Executive Offices
    Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark
    Item 2.  
       
      (a) Name of Person Filing
    Samsara BioCapital, L.P. (“Samsara LP”)
    Samsara BioCapital GP, LLC (“Samsara GP”)
    Srinivas Akkaraju (“Akkaraju”)
      (b) Address of Principal Business Office or, if none, Residence
    c/o Samsara BioCapital, LLC
    628 Middlefield Road
    Palo Alto, CA 94301
      (c) Citizenship
    Entities:

    Individuals:

     

    Samsara LP - Delaware
    Samsara GP - Delaware
    Akkaraju -      United States

      (d) Title of Class of Securities
    Common Stock, $0.001 par value (“Common Stock”)
      (e) CUSIP Number
    449778 10 9

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable
       
    Item 4. Ownership

     

    The following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 is provided as of December 18, 2023:

     

    Reporting
    Persons
     

    Shares Held

    Directly

      

    Sole

    Voting

    Power

      

    Shared

    Voting

    Power

      

    Sole

    Dispositive

    Power

      

    Shared

    Dispositive

    Power

      

    Beneficial

    Ownership

       Percentage of Class (2) 
    Samsara LP (1)   3,640,015    0    3,640,015    0    3,640,015    3,640,015    5.5%
    Samsara GP (1)   0    0    3,640,015    0    3,640,015    3,640,015    5.5%
    Akkaraju (1)   0    0    3,640,015    0    3,640,015    3,640,015    5.5%

     

      (1) These shares are held by Samsara LP. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is the managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.
      (2) This percentage is calculated based on 65,880,914 shares of Common Stock outstanding as of November 10, 2023, as reported in the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed by the Issuer with the SEC on November 13, 2023.

     

    5 

     

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable
     
    Item 8. Identification and Classification of Members of the Group
       
      Not applicable
     
    Item 9. Notice of Dissolution of Group
       
      Not applicable
     
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

    6 

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: December 18, 2023

     

    Samsara BioCapital, L.P.  
       
    By: Samsara BioCapital GP, LLC  
    its General Partner  
         
    By: /s/ Srinivas Akkaraju  
      Name: Srinivas Akkaraju  
      Title: Managing Member  
         
    Samsara BioCapital GP, LLC  
       
    By: /s/ Srinivas Akkaraju  
      Name: Srinivas Akkaraju  
      Title: Managing Member  
         
    /s/ Srinivas Akkaraju  
    Srinivas Akkaraju  

     

      ATTENTION  
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

    7 

     

     

    Exhibit(s):

     

    AJoint Filing Agreement

     

    8 

     

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of IO Biotech, Inc. is filed on behalf of each of us.

     

    Dated: December 18, 2023

     

    Samsara BioCapital, L.P.  
       
    By: Samsara BioCapital GP, LLC  
    its General Partner  
         
    By: /s/ Srinivas Akkaraju  
      Name: Srinivas Akkaraju  
      Title: Managing Member  
         
    Samsara BioCapital GP, LLC  
       
    By: /s/ Srinivas Akkaraju  
      Name: Srinivas Akkaraju  
      Title: Managing Member  
         
    /s/ Srinivas Akkaraju  
    Srinivas Akkaraju  

     

     

     

    Get the next $IOBT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IOBT

    DatePrice TargetRatingAnalyst
    11/30/2021$21.00Overweight
    Morgan Stanley
    11/30/2021Outperform
    Cowen & Co.
    11/30/2021$20.00Buy
    Jefferies
    More analyst ratings

    $IOBT
    SEC Filings

    View All

    SEC Form 10-Q filed by IO Biotech Inc.

    10-Q - IO Biotech, Inc. (0001865494) (Filer)

    8/14/25 4:45:18 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - IO Biotech, Inc. (0001865494) (Filer)

    8/14/25 4:31:42 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech Inc. filed SEC Form 8-K: Other Events

    8-K - IO Biotech, Inc. (0001865494) (Filer)

    8/11/25 8:00:33 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Smith David V

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    6/6/25 4:27:46 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hunter Heidi

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    6/6/25 4:27:20 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hirth Peter

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    6/6/25 4:26:55 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $IOBT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Morgan Stanley initiated coverage on IO Biotech with a new price target

    Morgan Stanley initiated coverage of IO Biotech with a rating of Overweight and set a new price target of $21.00

    11/30/21 7:56:32 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cowen & Co. initiated coverage on IO Biotech

    Cowen & Co. initiated coverage of IO Biotech with a rating of Outperform

    11/30/21 7:16:27 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on IO Biotech with a new price target

    Jefferies initiated coverage of IO Biotech with a rating of Buy and set a new price target of $20.00

    11/30/21 6:57:41 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hunter Heidi bought $20,884 worth of shares (15,000 units at $1.39) (SEC Form 4)

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    6/2/25 7:53:36 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Ahmad Qasim Iftikhar bought $26,553 worth of shares (31,350 units at $0.85) (SEC Form 4)

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    12/26/24 8:50:34 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Zocca Mai-Britt bought $10,120 worth of shares (12,500 units at $0.81), increasing direct ownership by 33% to 49,891 units (SEC Form 4)

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    12/23/24 6:56:14 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

    Announced clinical improvement in progression free survival observed in pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (pembrolizumab) for the treatment of first-line advanced melanoma, but statistical significance narrowly missed; company plans to meet with FDA this fall to discuss data and next steps for a potential regulatory submissionEnded second quarter with approximately $28.1 million in cash and cash equivalents; the company expects that our cash position, together with €12.5 million in proceeds from the second tranche of the European Investment Bank (EIB) loan facility received on July 4, 2025, will be sufficient to continue funding our operations into the first quarter of 2026Co

    8/14/25 4:05:00 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biotech Stocks Rally as Oncology Market Targets $866B by 2034

    Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- Equity Insider News Commentary – Despite alarming federal budget cuts that stand to potentially harm the national battle against cancer, it appears that the private sector continues to step up, with hundreds of millions of VC dollars pouring into oncology ventures so far in 2025. While there has been a recent victory in the Senate to restore $15 million for the Pancreatic Cancer Research Program (PCARP), the prior elimination of the only federal program dedicated solely to researching pancreatic cancer served as a stark reminder of these ongoing funding challenges. This dyn

    8/14/25 12:30:00 PM ET
    $IOBT
    $OLMA
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

    Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab monotherapy, HR=0.77 (CI 0.58-1.00), (p=0.056), with median PFS (mPFS) of 19.4 months vs. 11.0 months, respectively; the results on the primary endpoint narrowly missed the study's statistical significance threshold of p≤0.045 In patients enrolled in this study without prior neo-adjuvant/adjuvant anti-PD-1 treatment (n=371), patients treated with Cylembio plus pembrolizumab achieved improvement in PFS, HR: 0.74 (CI 0.56-0.98) (nominal p=0.037), with mPFS of 24.8 months vs. 11.0 months for the cont

    8/11/25 8:00:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Leadership Updates

    Live Leadership Updates

    View All

    IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

    -- Enrollment Completed Ahead of Schedule --       -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, completed enrollment in its neoadjuvant/adjuvant Phase 2 basket trial (IOB-032/PN-E40). The trial is studying IO102-IO103, the company's lead investigational therapeutic cancer vaccine candidate, in combination with Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), given before (neoadjuvant) and after (adjuvant) surgery with curative intent in patients with resectab

    1/9/25 8:05:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

    NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company's lead cancer vaccine candidate currently in a pivotal Phase 3 trial. Ms. Shamsaei joins the company's executive team, reporting to IO Biotech CEO Mai-Britt Zocca, Ph.D., and is based in the United States. "Marjan's extensive oncology product commercialization and growth strategy expertise will be invaluable as we progress into the commercia

    4/15/24 8:30:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

    NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company's chief business officer. Dr. Miyara, who has more than 17 years of experience in the pharmaceutical industry, will be responsible for global business development activities including strategic partnerships. Dr. Miyara will be based in the United States, report to IO Biotech's CEO, Mai-Britt Zocca, Ph.D., and be a member of the company's executive team, effective immediately. "We are very excited to welcome

    4/5/24 8:30:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Financials

    Live finance-specific insights

    View All

    IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

    Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab monotherapy, HR=0.77 (CI 0.58-1.00), (p=0.056), with median PFS (mPFS) of 19.4 months vs. 11.0 months, respectively; the results on the primary endpoint narrowly missed the study's statistical significance threshold of p≤0.045 In patients enrolled in this study without prior neo-adjuvant/adjuvant anti-PD-1 treatment (n=371), patients treated with Cylembio plus pembrolizumab achieved improvement in PFS, HR: 0.74 (CI 0.56-0.98) (nominal p=0.037), with mPFS of 24.8 months vs. 11.0 months for the cont

    8/11/25 8:00:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

    NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, 2025, at 8:30 AM ET to disclose the topline results of the pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio (imsapepimut and etimupepimut, adjuvant) in combination with pembrolizumab vs. pembrolizumab alone as a first-line treatment for unresectable or metastatic (advanced) melanoma. Webcast and Conference Call Information The IO Biotech management team will host a webcast/conference call

    8/10/25 8:00:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech Announces 2022 Fourth-Quarter and Year-End Results

    Enrollment in the company's Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma accelerated in the second half of 2022; the company expects to enroll 75% of patients by mid-2023 and fully enroll the trial by the end of 2023.The Phase 3 trial protocol calls for an interim analysis of overall response rate one year after 75% of patients have been randomized; this interim analysis could allow for submission of a Biologics License Application for an accelerated approval in the United States.The company continues to enroll patients in its Phase 2 basket study (IOB-022/KN-D38) evaluating IO102-IO103 in combination with pembrolizumab in patients with non-small cell lung cancer, head and nec

    3/14/23 4:11:47 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by IO Biotech Inc.

    SC 13G/A - IO Biotech, Inc. (0001865494) (Subject)

    11/13/24 5:30:28 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by IO Biotech Inc.

    SC 13D/A - IO Biotech, Inc. (0001865494) (Subject)

    9/17/24 9:01:25 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by IO Biotech Inc. (Amendment)

    SC 13G/A - IO Biotech, Inc. (0001865494) (Subject)

    5/14/24 9:35:27 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care